ProThera enters agreement with Takeda for acute inflammatory condition treatment development

PROVIDENCE – ProThera Biologics Inc. has entered into a global licensing agreement with Takeda Pharmaceutical Co. Ltd. to develop a novel plasma-derived treatment of acute inflammatory conditions, the company announced Thursday.  The Inter-alpha Inhibitor Proteins therapy has the potential to deliver a disease-modifying treatment for a range of acute inflammatory diseases, the company said. The…

Want More?

Subscribe or register with Providence Business News to keep reading.

REGISTER
for 2 more stories

Subscribe now for $1 for 4 weeks
Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -